Tourmaline Bio, Inc. announced that, upon recommendation by the Nominating and Corporate Governance Committee of the Company's board of directors, the Board appointed Clay Siegall to serve as a director of the Company, effective as of December 13, 2023. The Company also announced that the Board has unanimously approved the appointment of Dr. Siegall as Chair of the Board, as well as to serve as a member of the Compensation Committee of the Board. Dr. Siegall?s term will expire at the Company?s 2024 annual meeting of stockholders.

Dr. Siegall is currently President, Chief Executive Officer and Chairman of the Board of Directors of Immunome, Inc. (Nasdaq: IMNM). Dr. Siegall previously founded Seattle Genetics (more recently Seagen Inc.) in January 1998. He served in roles including Chief Scientific Officer, President, Chief Executive Officer and Chairman of the Board through May 2022.

Dr. Siegall has served as a director of multiple companies, including at Nurix Therapeutics, Inc., Umoja Biopharma, Inc., a privately held biotechnology company where he served as Chairman of the Board, Alder BioPharmaceuticals, Inc., which was acquired by H. Lundbeck A/S in 2019, Mirna Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.